 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Janssen Pharmaceutica NV
|
-
Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V.
(11 Jun 2008)
Astex Therapeutics Limited announced that Astex and Janssen Pharmaceutica have entered into a research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer. The new agreement grants Janssen ...
-
Galapagos achieves EUR 3.4 million milestone payment from Janssen Pharmaceutica NV
(29 Jan 2008)
Galapagos NV announced achievement of a milestone under its alliance agreement in rheumatoid arthritis with Janssen Pharmaceutica NV. The milestone triggered a cash payment of EUR 3.4 million to Galapagos.On 24 October 2007, Galapagos announced an ...
-
Galapagos enters into oncology target discovery collaboration with Janssen Pharmaceutica
(04 Jan 2008)
Galapagos NV announced a new two-year target discovery collaboration between Janssen Pharmaceutica and BioFocus DPI, Galapagos' service division, in the field of oncology. BioFocus DPI will apply Galapagos' proprietary adenoviral platform to ...
-
Galapagos enters into global alliance with Janssen Pharmaceutica on rheumatoid arthritis research
(25 Oct 2007)
Multi-target alliance to discover, develop, and commercialize oral small molecule therapeutics for rheumatoid arthritis
Galapagos NV announced that it has entered into a worldwide multi-target alliance with Janssen Pharmaceutica NV, a Johnson & Johnson company, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis (RA). ...
-
Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development
(09 Mar 2007)
Galapagos NV announced that its service division, BioFocus DPI, has entered into an agreement to supply small molecule compounds for drug discovery to the Johnson & Johnson Pharmaceutical Research & Development Division of Janssen Pharmaceutica NV ...
-
KINAXO Announces Agreement with Johnson & Johnson Pharmaceutical Research & Development
(15 Jan 2007)
KINAXO Biotechnologies GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica. Under the agreement, KINAXO will use the KinaTorTM technology to ...
-
PamGene Platform Adopted for Kinase Drug R&D Program
(13 Mar 2006)
Collaboration with Johnson & Johnson Pharmaceutical Research & Development
PamGene International BV and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica NV have announced significant progress in their kinase profiling collaboration. After extensive evaluation, PamGene's ...
Additional information
Janssen Pharmaceutica NV
Beerse, Belgium
Company
|
|
|
|
|
|
Top
